Gut bacteria compound cuts children's allergy and asthma risk by 60 percent

Researchers at Denmark's Technical University have identified a natural compound produced by gut bacteria that dramatically reduces how likely children are to develop allergies and asthma. The finding points to a preventive strategy that could reshape how we approach these increasingly common childhood conditions.

Allergies and asthma affect more children every year, but a new international study suggests the answer might already live inside us. The research, published in Nature Microbiology, tracked 147 children from birth to age five across Sweden, Germany, and Australia. The team discovered that infants colonized early with specific types of bifidobacteria—common gut microbes—produce a substance called 4-hydroxyphenyl lactate (4-OH-PLA) that essentially teaches the immune system not to overreact to harmless allergens.

Here's how it works: When your immune system encounters an allergen like pollen or a food protein, it produces an antibody called immunoglobulin E (IgE). This is the body's alarm molecule—it binds to allergens and triggers the cascade of symptoms: itching, eczema, hay fever, sometimes asthma. The higher your IgE levels, the greater your allergy risk. In laboratory tests using human immune cells, 4-OH-PLA reduced IgE production by 60 percent without dampening other immune functions. The compound essentially turns down the volume on a misfiring alarm system.

The window that shaped us

What's striking is how these protective bacteria arrive in the first place. Children born vaginally were 14 times more likely to acquire bifidobacteria from their mothers. Exclusive breastfeeding also increased colonization, as did early contact with other children. These are the mechanisms evolution built into human development—ways the immune system learns what to ignore and what to fight.

But modern life has made these bacteria rarer. Cesarean births, formula feeding, and reduced early childhood exposure have disrupted the microbial handoff that once happened automatically. This is where the research opens a door: if we can't always recreate those conditions, we might be able to replicate the benefit.

The team is now testing whether adding 4-OH-PLA directly—or enriching infant formula with bifidobacteria that produce it—could prevent allergies and asthma in children who miss out on natural colonization. The critical window is the first months of life, when the immune system is still forming its basic rules about what belongs and what doesn't.

If early trials at Aarhus University Hospital show positive results, a preventive supplement could be available within a few years. A full pharmaceutical treatment for children already diagnosed with allergies or asthma would take longer—up to a decade—since it requires formal drug development and clinical trials. But the path from laboratory discovery to real prevention is now visible.